Neutralisation of α-neurotoxins using human recombinant igg antibodies

In the field of recombinant antivenoms, a major hurdle to the development of antigen-binding proteins enabling sufficient toxin neutralization is the identification of antigen-binding proteins with both high affinity and broad cross-reactivity against venom toxins. Traditional antibody development approaches used failed to isolate antigen-binding proteins against venom toxins with such properties. The present disclosure describes the development of high-affinity human antibodies that show broadly-neutralizing effects against neurotoxic elapid snake venom in vitro and in vivo. The invention relates to antigen-binding proteins capable of binding to, blocking, or neutralizing two or more different α-neurotoxins. The disclosure also provides pharmaceutical compositions, kit of parts and kits for the treatment and diagnosis of snake envenomation.